CRISPR Therapeutics has been a volatile ride for shareholders, and the latest moves raise a straightforward question for ...

CRISPR Therapeutics (CRSP) has released its third quarter 2026 results, reporting revenue of US$12.67 million and a net loss ...

For years, CRISPR Therapeutics (NASDAQ: CRSP) has been the type of stock investors might call a home run swing. The company develops medicines using gene-editing technologies to treat or cure serious ...

CRISPR Therapeutics AG (CRSP) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2026. This widely-known consensus ...

Billionaire investor Cathie Wood, through her ARK ETFs, made big buys of CRISPR Therapeutics on Friday, Oct. 9, and Monday, Oct. 12.

CRISPR Therapeutics' only approved product may experience increased demand. The biotech could also see significant clinical progress with some key candidates. Although the stock might jump on positive ...

Stock forecast & analyst price target predictions based on 13 analysts offering 12-month price targets for CRSP in the last 3 months.

CRISPR Therapeutics AG remains a Buy, supported by a robust pipeline, prudent capital management, and a deep Vertex partnership despite slow Casgevy adoption. Casgevy's market penetration is limited ...

CRISPR Therapeutics is a developer of gene therapies for disease, by the way. Specifically, the company's founders figured out how to cut a damaged segment out of a DNA strand and replace it with a ...